SOMERSET, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO) (“CareCloud” or the “Company”), a leader in AI-powered healthcare technology and revenue cycle management solutions, today announced that its common stock rose approximately 70% during the second quarter of 2025, making it among the top gainers in the Russell Microcap® Index for the period. The Company was officially added to the Russell Microcap Index effective June 30, 2025, following the annual reconstitution of the R ...

SINGAPORE, July 10, 2025 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading AI-powered, Bitcoin-first education group, today announced that further to receiving shareholder and board approval for a share buyback of up to 20% of the Company’s issued ordinary shares, on July 9, 2025 the Company bought back one million shares of its stock on the open market at an average price of $1.30 per share. At Genius Group’s Annual General Meeting (AGM) on July 7, 2 ...

ETX-312 well tolerated at exaggerated dose levels in GLP-compliant toxicology studies GMP manufacturing of clinical trial batch successfully completed On track for CTA submission in Q4 2025 LONDON, July 10, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, today announced significant progress on its lead candidate, ETX-312, a GalOmic siRNA therapy for the treatment of metabolic dysfunction-associated steat ...

业绩总结 - 2020财年产品预订预计达到约10亿美元，超出之前的865-900百万美元指导范围[7] - 2020财年总收入预计在890-892百万美元之间，超出之前的881-887百万美元指导范围[7] - 2020财年非GAAP EBITDA预计在157-159百万美元之间[7] - 2020年GAAP净收入为28600万至30600万美元，非GAAP净收入为107800万至109800万美元[55] - 2020年非GAAP营业利润率约为13%，预计到2025年将达到约21%[45] - 2020年非GAAP EBITDA利润率约为17%，预计到2025年将达到约25%[45] 未来展望 - 2021财年总收入指导为10.85-11.05亿美元，非GAAP EBITDA指导为2.28-2.40亿美元，非GAAP每股收益指导为3.38-3.58美元[7] - 预计2021-2025年收入年复合增长率（CAGR）为14-15%，其中有机增长为11-12%，无机增长为3%[10] - 预计2021年至2025年总收入年复合增长率目标为14-15%（有机增长11-12%，无机增长3%）[52] - 2021年预计收入为10.85亿至11.05亿美元，2025年预计收入为19亿至20亿美元[43] - 预计到2025年，SaaS、订阅软件和技术驱动服务将占收入的20-30%[46] 用户数据与市场地位 - Omnicell在美国医院的安装基础中占比约为50%[31] - Omnicell的客户保留率超过99%[35] - Omnicell的总可寻址市场（TAM）超过700亿美元[32] - 公司与美国前300大医疗系统中的145个建立了独家合作关系[46] 财务指标 - 预计2021-2025年非GAAP EBITDA利润率将增加约400个基点[10] - 2020年非GAAP EBITDA为157000万至159000万美元，非GAAP EBITDA利润率为17.6%-17.9%[58] - 公司在过去10年中总股东回报率为731%，超越S&P医疗保健指数328%[48] 收入增长目标 - 2020-2025年SaaS、订阅软件和技术驱动服务的收入年复合增长率目标为50%[10] - 2020年至2025年目标收入年复合增长率（CAGR）约为50%[40]

SharkNinja (NYSE: SN ) is a global product design and technology company based in Massachusetts. Made up of two flagship companies, Shark (cleaning devices and technologies) and Ninja (cooking and food preparation devices), the company has been performing well in recent months, afterLW Research is run by a qualified accountant working in the financial services sector mainly in private equity, hedge funds, asset management and venture capital. Since my time working as an accountant I've become extremely well ...

ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) NEW YORK and NORTH CHICAGO, Ill., July 10, 2025 (GLOBE NEWSWIRE) -- IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), and AbbVie (NYSE: ABBV) today announced an exclusive licensing agreement for IGI’s lead investigational asset, ISB 2001, developed using IGI’s proprietary BEAT® protein platform, for oncology and autoimmune diseases. “Multispeci ...

ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM)NORTH CHICAGO, Ill. and NEW YORK, July 10, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive licensing agreement for IGI's lead investigational asset, ISB 2001, developed using IGI's proprietary BEAT® protein platform, for oncology and autoimmune diseases."Multispecifics ...

[IMAGES BELOW] Sustained complete resolution of temporal lobe brain metastasis and continued orbital tumor reduction after >18 months of treatment“Eye bulging” metastatic breast cancer patient had failed 8 prior regimens, including antibody-drug conjugate (ADC) therapyPatient remains on BriaCell’s Phase 2 study with 29 treatment cycles completed PHILADELPHIA and VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or t ...

（图片来源：摄图网） 在量子计算领域，中国同样交出了一份亮眼的成绩单。 量子通信，是利用量子力学原理对信息进行编码、传输和处理的一种新型通信方式，以其高度的安全性和传 输效率，成为当今信息通信领域的前沿技术，是量子信息学的核心分支。具有不可克隆、不可分割和不可预 测的特性，能够从根本上保证信息传输的绝对安全。 尽管2023年中国量子通信市场规模仅约6亿元，但随着国防、信息安全需求的不断增长，其战略价值已获全 球认可。量子通信正从实验室走向产业化，成为守护国家信息安全的"国之重器"。 7月6日，中国科协副主席、中国科学技术大学常务副校长、中国科学院院士潘建伟在第二十七届中国科协年 会主论坛上表示，我国在量子通信领域已处于国际引领地位。他指出，我国在量子通信领域取得了一系列重 要成果，包括成功发射"墨子号"量子科学实验卫星，建成"京沪干线"地面光纤网络和国家广域量子保密通信 骨干网，并实现了与奥地利、南非的洲际量子密钥分发。此外，我国科学家还在合肥完成首批严格的器件无 关量子密钥分发实验，为信息安全提供了坚实保障。 潘建伟还提到，我国在量子计算领域处于国际第一方阵，在量子精密测量领域部分方向处于国际领先或先进 水 ...

The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.What Are Smart Beta ETFs?The ETF industry has traditionally been dominated by products based on market capitalization weighted indexes that are designed to represent the market or a particular segment of the market.Investors who believe in market efficiency should consider market cap indexes, as they replicate market returns in a lo ...